



# WundForum

## Literatur-Service

J. Dissemond

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen

### Aktuelle und zukünftige Therapiestrategien von MRSA in chronischen Wunden

**WundForum 2/2003**  
**Forschung**  
**Seiten 16-19**

Ameen H, Moore K, Lawrence JC, Harding KG.  
Investigating the bacterial barrier properties of four contemporary wound dressings. *J Wound Care* 2000; 9: 385-388

Anonymous.  
Staphylococcus aureus resistant to vancomycin-United States 2002. *MMWR Morb Mortal Wkly Rep* 2002; 51: 565-567

Bonn D.  
Maggot therapy: an alternative for wound infection. *Lancet* 2000; 356: 1174

Boyce JM.  
Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge. *Eur J Clin Microbiol Infect Dis* 1994; 13: 45-49

Chiller K, Selkin BA, Murakawa GJ.  
Skin microflora and bacterial infections of the skin. *J Invest Dermatol Symp Proc* 2001; 6: 170-174

Colsky AS, Kirsner RS, Kerdel FA.  
Analysis of antibiotic susceptibilities of wound flora in hospitalised dermatology patients: the crisis of antibiotic resistance has come to the surface. *Arch Dermatol* 1998; 134:1006-1009

Cookson B.  
Failure of mupirocin-resistant staphylococcus to inactivate mupirocin. *Eur J Clin Microbiol Infect Dis* 1989; 8: 1038-1040

Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y.  
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. *Clin Infect Dis* 2003; 36: 53-59

Dissemond J, Koppermann M, Esser S, Schultewolter T, Goos M, Wagner SN.  
Therapie eines Methicillin-resistenten Staphylokokkus aureus (MRSA) im Rahmen der Behandlung eines chronischen Ulcus mittels Biochirurgie. *Hautarzt* 2002; 53: 608-612

Filius PM, Gyssens IC.  
Impact of increasing antimicrobial resistance on wound management. *Am J Clin Dermatol* 2002; 3: 1-7

Frenay HM, Vandenbrocke-Grauls, CM, Molkenboer MJ, Verhoef J.  
Long-term carriage, and transmission of methicillin-resistant Staphylococcus aureus after discharge from hospital. *J Hosp Infect* 1992; 22: 207-215

- Gelder G, Zwing M, Trautmann M, Georgieff M, Wiedeck H.  
Therapie und Prophylaxe bei MRSA-Infektionen auf Intensivstationen. *Intensivmed* 1999; 36: 612-618
- Gloor M, Becker A, Wasik B, Kniehl E.  
Triclosan, a topical dermatologic agent. In vitro- and in vivo studies on the effectiveness of a new preparation in the New German Formulary. *Hautarzt* 2002; 53: 724-729
- Gonzalez-Zorn B, Courvalin P.  
vanA-mediated high level glycopeptide resistance in MRSA. *Lancet Infect Dis* 2003; 3: 67-68
- Grohs P, Kitzis MD, Gutmann L.  
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamycin, ciprofloxacin, fusidic acid, and rifampin against staphylococcus aureus. *Antimicrob agents chemother* 2003; 47: 418-420
- Halbert AR, Stacey MC, Rohr JB, Jopp-McKay A.  
The effect of bacterial colonization on venous ulcer healing. *Australas J Dermatol* 1992; 33: 75-80
- Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D.  
Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. *Antimicrob Agents Chemother* 1999; 43: 1412-1416
- Hernandez R.  
Systemic antibiotics: a review and their use in chronic wounds. *Dermatologic Therapy* 1999; 9: 44-62
- Hernandez-Richter T, Schardey HM, Heiss MM, Lohlein F, Schildberg FW.  
Experimental study of antiseptic (tauroline, taurilidine) and antibiotic (sulmycin implant) drugs in vascular prosthesis infections in a standardized infection model. *Zentralbl Chir* 2001; 126: 407-412
- Hiramatsu J.  
The emergence of staphylococcus aureus with reduced susceptibility to vancomycin in Japan. *Am J Med* 1998; 104: 7-10
- Huang SS, Platt R.  
Risk of Methicillin-Resistant Staphylococcus aureus Infection after Previous Infection or Colonization. *Clin Infect Dis* 2003; 36: 281-285
- Ibelings MM, Bruining HA.  
Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. *Eur J Surg* 1998; 164: 411-418
- Ida T, Tsushima M, Ishii T, Atsumi K, Tamura A.  
CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant staphylococcus aureus and Pseudomonas aeruginosa. *J Infect Chemother* 2002; 8: 138-1444
- Jevons MP.  
Celbenin resistant staphylococci. *Br Med J* 1961; 1: 124-125
- Kac G, Buu-Hoi A, Herisson E, Biancardini P, Debure C  
Methicillin-resistant staphylococcus aureus. Nosocomial acquisition and carrier state in a wound care center. *Arch Dermatol* 2000; 136: 735-739
- Kloth LC.  
Physical modalities in wound management: UVC, therapeutic heating and electrical stimulation. *Ostomy Wound Manage* 1995; 41: 18-27
- König DP, Randerath O, Hackenbroch MH.  
Nosokomiale Infektionen mit Methicillin-resistenten Staphylococcus aureus (MRSA) und epidermidis (MRSE) Stämmen. *Unfallchirurg* 1999; 102: 323-328
- Lackey DB, Groziak MP, Sergeeva M, Beryt M, Boyer C, Stroud RM, Sayre P, Park JW, Johnston P, Salomon D, Shepard HM, Pegram M.  
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. *Biochem Pharmacol* 2001; 61: 179-189
- Leclercq R.  
Safeguarding future antimicrobial options: strategies to minimize resistance. *Clin Microbiol Infect* 2001; 7: 18-23
- Li Q, Lee JY, Castillo R, Hixon MS, Pujol C, Doppalapudi VR, Shepard HM, Lobl TJ, Chan MF.  
NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strains. *Antimicrob Agents Chemother* 2002; 46: 1262-1268
- Linde HJ, Lehn N.  
Methicillin-resistente Staphylococcus aureus (MRSA). *Hautarzt* 2002; 53: 690-701

- Lindenmayer JM, Schoenfeld S, O'Grady R, Carney JK. Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. *Arch Intern Med* 1998; 158: 895-899
- Lowy FD. Staphylococcus aureus infections. *N Engl J Med* 1998; 339: 520-532
- Malouin F, Blais J, Chamberland S, Hoang M, Park C, Chan C, Mathias K, Hakem S, Dupree K, Liu E, Nguyen T, Dudley MN. RWJ-54428 (MC-02,479), a New Cephalosporin with High Affinity for Penicillin-Binding Proteins, Including PBP 2a, and Stability to Staphylococcal Beta-Lactamases. *Antimicrob Agents Chemother* 2003; 47: 658-664
- McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. *Nature* 1998; 394: 531-532
- Mertz PM, Oliveira-Gandia MF, Davis SC. The evaluation of a cadexomer iodine wound dressing on methicillin resistant staphylococcus aureus (MRSA) in acute wounds. *Dermatol Surg* 1999; 25: 89-93
- Muder RR, Brennen C, Wagener MM, Vickers RM, Rihs JD, Hancock GA, Yee YC, Miller JM, Yu VL. Methicillin-resistant Staphylococcal colonisation and infection in a long-term care facility. *Ann Intern Med* 1991; 114: 107-112
- Natarajan S, Williamson D, Grey J, Harding KG, Cooper RA. Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. *J Dermatolog Treat* 2001; 12: 33-36
- O'Meara S, Cullum N, Majid M, Sheldon T. Systemic review of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. *Health Technol Assessment* 2000; 4: 1-237
- Ohwada A, Sekiya M, Hanaki H, Arai KK, Nagaoka I, Hori S, Tominaga S, Hiramatsu K, Fukuchi Y. DNA vaccination by mecA sequence evokes an anti-bacterial immune response against methicillin-resistant Staphylococcus aureus. *J Antimicrob Chemother* 1999; 44: 767-774
- Okano M, Nagouchi S, Tabata K, Matsumoto Y. Topical gentian violet for cutaneous infection and nasal carriage with MRSA. *Int J Dermatol* 2000; 39: 942-944
- Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. *Antimicrob Agents Chemother* 2002; 46: 2155-2161
- Paladino JA. Linezolid: an oxazolidinone antimicrobial agent. *Am J Health Syst Pharm* 2002; 59: 2413-2425
- Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. *Med Clin North Am* 2001; 85: 1-17
- Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S, Perneger TV. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. *Infection Control Programme. Lancet* 2000; 356: 1307-1312
- Pujol M, Pena C, Pallares R, Ariza J, Ayats J, Dominguez MA, Gudiol F. Nosocomial Staphylococcus aureus bacteriemia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. *Am J Med* 1996; 100: 509-516
- Reimer K, Wichelhaus TA, Schafer V, Rudolph P, Kramer A, Wutzler P, Ganzer D, Fleischer W. Antimicrobial effectiveness of polyiodine-iodine and consequences for new application areas. *Dermatology* 2002; 204: 114-120
- RKI. Erstes Auftreten von MRSA mit verminderter Glykopeptidresistenz in Deutschland nachgewiesen. *Epidem Bull RKI* 1998; 36: 255-256
- RKI. Zunahme von MRSA in deutschen Krankenhäusern. *Epidem Bull RKI* 2000; 9: 70-71
- Roghmann MC, Siddiqui A, Plasance K, Standiford H. MRSA colonization and the risk of MRSA bacteriemia in hospitalized patients with chronic ulcers. *J Hosp Infect* 47: 98-103
- Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. *N Engl J Med* 2002; 346: 491-496

- Sieradzki K, Roberts RB, Haber SW, Tomasz A.  
The development of vancomycin resistance in a patient with methicillin-resistance *Staphylococcus aureus* infection. *N Engl J Med* 1999; 340: 517-523
- Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, Hafkin B.  
Randomized comparison of linezolid versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. *Microb Agents Chemother* 2000; 44: 3408-3413
- Swanston WH.  
Methicillin resistant *staphylococcus aureus*. *West Indian Med J* 1999; 48: 20-22
- Thai TP, Houghton PE, Campell KE, Wodbury MG.  
Ultraviolet light C in the treatment of chronic wounds with MRSA: a case study. *Ostomy Wound Management* 2002; 48: 52-60
- Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ.  
Linezolid resistance in a clinical isolate of *Staphylococcus aureus*. *Lancet* 2001; 358: 207-208
- Veien NK.  
The clinician's choice of antibiotics in the treatment of bacterial skin infection. *Br J Dermatol* 1998; 53: 30-36
- von Eiff C, Peters G.  
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. *J Antimicrobial Chemotherapy* 1999; 43: 569-573
- Voss A, Machka K, Lenz W, Milatovic D.  
Vorkommen, Häufigkeit und Resistenzverhalten von Methicillin-resistenten *Staphylococcus aureus* Stämmen in Deutschland. *Dtsch Med Wschr* 1992; 117: 1907-1912
- Voss A, Milatovic D, Wallrauch Schwarz C, Rosdahl VT, Braveny I.  
Methicillin-resistant *staphylococcus aureus* in Europe. *Eur J Clin Microbiol Infect Dis* 1994; 13: 50-55
- Westh H, Hougaard D, Vuust J, Rosdahl VT.  
Prevalence of *erm* gene classes in erythromycin resistant *staphylococcus aureus* strains isolated between 1959 and 1988. *Antimicrob Agents Chemother* 1995; 39: 369-373
- Whitby M, McLaws ML, Berry G.  
Risk of death from methicillin-resistant *staphylococcus aureus* bacteraemia: a meta-analysis. *Med J Aust* 2001; 175: 264-267
- Wright JB, Lam K, Burrell RE.  
Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. *Am J Infect Control* 1998; 26: 572-577
- Zabel LT, Lenz W, Schwab E.  
Molekulare und phänotypische Charakterisierung von Methicillin-resistenten *Staphylococcus aureus*-Isolaten. *Unfallchirurg* 2000; 103: 557-563
- Zeina B, Greenman J, Purcell WM.  
Das B. Killing of cutaneous microbial species by photodynamic therapy. *Br J Dermatol* 2001; 144: 274-278